Charles River and Valo Launch Logica, an AI-Based Integrated Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets | News
WILMINGTON, Mass. & BOSTON–(BUSINESS WIRE)–April 27, 2022–
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Logica TM, an artificial intelligence (AI)-based drug solution that directly translates customers’ biological insights into preclinical assets optimized. Logica leverages Valo’s AI-powered Opal compute platform and Charles River’s cutting-edge preclinical expertise, providing customers with transformed drug discovery with a single integrated offering that seamlessly translates targets nominating candidates.
This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220427005134/en/
“Through our partnership with Valo, we are integrating the capabilities of the Charles River laboratory with AI-driven molecular design that is changing the industry to provide our customers with highly advanced leads and candidates, while linking the costs of customers to value generation,” said Birgit Girshick, Corporate Executive Vice President and Chief Operating Officer, Charles River. “AI-based solutions are advancing drug discovery and this is the kind of innovation our industry needs to finally bring effective treatments to patients faster.”
“Valo is thrilled to partner with Charles River on this first-of-its-kind offering,” added David Berry, MD, Ph.D., Founder and CEO of Valo. “We are creating an opportunity to fully outsource small molecule discovery while providing a true risk-sharing model with advanced leads and candidates with the goal of helping companies scale faster, translating more information biologics as candidates to make better drugs for patients, faster.”
Logica’s Advanceable Lead (Logica-AL™) and Candidate (Logica-C™) programs, available exclusively from Charles River, are part of a multi-year strategic partnership that Charles River and Valo announced earlier this year. Logica-AL aims to provide customers with powerful and highly advanced series with desired features, such as in vitro understanding of absorption, distribution, metabolism and excretion (ADME) and selectivity profiles. Additionally, the Logica-C offering will utilize the advanced leads and trained predictive models to rapidly advance the program, with the ultimate goal of delivering a development candidate that has undergone the necessary safety and efficacy testing and is ready for studies allowing the IND.
Logica uses state-of-the-art predictive models, chemical design and synthesis capabilities, DNA-encoded libraries, silicone high-throughput screening from Valo’s Opal computing platform as well as Charles River’s industry-leading capabilities in all aspects of discovery optimization, including high-throughput screening, medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission, coming together for the first time to create a unified target-candidate, compute-powered offering. Logica combines approaches that have been shown to produce a series of advanced leads 90% of the time and deliver candidates for development 58% of the time. The products will be offered with most of the costs to the customer tied to success.
About Valo Health
Valo Health, Inc (“Valo”) is a technology company created to transform the drug discovery and development process using human-centric data and artificial intelligence (“AI”) computation. As a digitally native company, Valo aims to fully integrate human-centric data across the drug development lifecycle into a single unified architecture, accelerating the discovery and development of life-changing drugs. while simultaneously reducing cost, time and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to turn data into valuable insights that can accelerate discovery and enable Valo to advance a strong portfolio of programs in cardiovascular, metabolic, renal, oncological and neurodegenerative. Founded by Flagship Pioneering and based in Boston, MA, Valo also has offices in Lexington, MA, New York, NY, San Francisco, CA, and Branford, CT. To learn more, visit www.valohealth.com.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the world accelerate their drug research and development efforts. Our dedicated employees strive to provide customers with exactly what they need to improve and accelerate the discovery, early development and safe manufacturing of new therapies for patients in need. To learn more about our unique portfolio and scope of our services, visit www.criver.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220427005134/en/
CONTACT: Charles River Investor:
Corporate Vice President, Investor Relations
[email protected] River Media:
Corporate Vice President and Head of Communications
[email protected] Health Investor:
[email protected] Health Media:
Vice President and Head of Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
KEYWORD INDUSTRY: RESEARCH TECHNOLOGY MEDICAL DEVICES OTHER TECHNOLOGIES NANOTECHNOLOGY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE
SOURCE: Charles River Laboratories International, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 04/27/2022 08:00 / DISK: 04/27/2022 08:02